New criteria of resectability for pancreatic cancer: A position paper by the Japanese Society of Hepato-Biliary-Pancreatic Surgery (JSHBPS).

Published on Oct 20, 2021in Journal of Hepato-biliary-pancreatic Sciences7.027
路 DOI :10.1002/JHBP.1049
Atsushi Oba2
Estimated H-index: 2
(CU: University of Colorado Boulder),
Marco Del Chiaro34
Estimated H-index: 34
(CU: University of Colorado Boulder)
+ 18 AuthorsItaru Endo66
Estimated H-index: 66
(YCU: Yokohama City University)
The symposium "New criteria of resectability for pancreatic cancer" was held during the 33nd meeting of the Japanese Society of Hepato-Biliary-Pancreatic Surgery (JSHBPS) in 2021 to discuss the potential modifications that could be made in the current resectability classification. The meeting focused on setting the foundation for developing a new prognosis-based resectability classification that is based on the tumor biology and the response to neoadjuvant treatment (NAT). The symposium included selected experts from Western and Eastern high-volume centers who have discussed their concept of resectability status through published literature. During the symposium, presenters reported new resectability classifications from their respective institutions based on tumor biology, conditional status, pathology, and genetics, in addition to anatomical tumor involvement. Interestingly, experts from all the centers reached the agreement that anatomy alone is insufficient to define resectability in the current era of effective NAT. On behalf of the JSHBPS, we would like to summarize the content of the conference in this position paper. We also invite global experts as internal reviewers of this paper for intercontinental cooperation in creating an up-to-date, prognosis-based resectability classification that reflects the trends of contemporary clinical practice.
馃摉 Papers frequently viewed together
9 Authors (Friedrich Anger, ..., Stefan L枚b)
4 Authors (Betsy L. Appel, ..., Susan Tsai)
20194.43BMC Cancer
#1Ananya Panda (Mayo Clinic)H-Index: 13
#2Ishan Garg (Mayo Clinic)H-Index: 7
Last. Ajit H. Goenka (Mayo Clinic)H-Index: 11
view all 14 authors...
Background: Imaging biomarkers of response to neoadjuvant therapy (NAT) in pancreatic ductal adenocarcinoma (PDA) are needed to optimize treatment decisions and long-term outcomes. Objective: To investigate metrics from PET/MRI and CT for assessment of pathologic response of PDA to NAT and prediction of overall survival (OS). Methods: This retrospective study included 44 patients with 18F-FDG avid borderline resectable or locally advanced PDA on pre-treatment PET/MRI who also underwent post-NAT ...
#1Bradley N. Reames (UNMC: University of Nebraska Medical Center)H-Index: 19
#2Alex B. Blair (Johns Hopkins University)H-Index: 17
Last. Jin He (Johns Hopkins University)H-Index: 45
view all 12 authors...
MiniAn international survey of high-volume pancreas cancer surgeons revealed wide variations in management preferences, attitudes regarding contraindications to surgery, and the propensity to offer exploration. When presented with 6 hypothetical clinical vignettes using details from real patients th
#1Guopei Luo (Fudan University)H-Index: 23
#2Kaizhou Jin (Fudan University)H-Index: 21
Last. Xianjun Yu (Fudan University)H-Index: 52
view all 11 authors...
Carbohydrate antigen 19-9 (CA19-9) is the best validated biomarker and an indicator of aberrant glycosylation in pancreatic cancer. CA19-9 functions as a biomarker, predictor, and promoter in pancreatic cancer. As a biomarker, the sensitivity is approximately 80%, and the major challenges involve false positives in conditions of inflammation and nonpancreatic cancers and false negatives in Lewis-negative Individuals. Lewis antigen status should be determined when using CA19-9 as a biomarker. CA1...
#1Friedrich AngerH-Index: 5
#2Anna D枚ringH-Index: 2
Last. Stefan L枚bH-Index: 11
view all 11 authors...
International consensus criteria (ICC) have redefined borderline resectability for pancreatic ductal adenocarcinoma (PDAC) according to three dimensions: anatomical (BR-A), biological (BR-B), and conditional (BR-C). The present definition acknowledges that resectability is not just about the anatomic relationship between the tumour and vessels but that biological and conditional dimensions also are important. Patients鈥 tumours were retrospectively defined borderline resectable according to ICC. ...
#1Elena Rangelova (KI: Karolinska Institutet)H-Index: 15
#2Agnes Wefer (KI: Karolinska Institutet)H-Index: 2
Last. Marco Del Chiaro (KI: Karolinska Institutet)H-Index: 34
view all 9 authors...
: MINI: The overall survival and the survival after resection of patients with borderline resectable pancreatic cancer or locally advanced pancreatic cancer after neoadjuvant therapy (NAT) are similar. Resected patients had better survival than nonresected, irrespective of the type or whether full-dose NAT was given. For all preoperative values of Ca 19-9, surgical resection had positive impact on survival. OBJECTIVE: Neoadjuvant therapy (NAT) has become part of the multimodality treatment for b...
#1Raffaella Casolino (Glas.: University of Glasgow)H-Index: 2
#2Chiara Braconi (Glas.: University of Glasgow)H-Index: 29
Last. Talia Golan (Sheba Medical Center)H-Index: 23
view all 11 authors...
This review summarises the recent evidence on preoperative therapeutic strategies in pancreatic cancer and discusses the rationale for an imminent need for a personalized therapeutic approach in non-metastatic disease. The molecular diversity of pancreatic cancer and its influence on prognosis and treatment response, combined with the failure of "all-comer" treatments to significantly impact on patient outcomes, requires a paradigm shift towards a genomic-driven approach. This is particularly im...
#1Yuta Ushida (JFCR: Japanese Foundation for Cancer Research)H-Index: 4
#2Yosuke Inoue (JFCR: Japanese Foundation for Cancer Research)H-Index: 18
Last. Yu Takahashi (JFCR: Japanese Foundation for Cancer Research)H-Index: 17
view all 9 authors...
Abstract Background Previous studies on borderline resectable (BR) pancreatic cancer (PC) included patients with heterogenous preoperative states; however, the definition of resectability for PC has evolved. We aimed to investigate the prognostic factors for PC other than anatomical resectability in those who underwent upfront resection and discuss the optimal treatment strategy for PC. Methods We retrospectively examined 431 patients who underwent upfront surgery with curative intent between 20...
Pancreatic cancer is a聽devastating disease with a聽5-year survival rate of 20鈥25%. As approximately only 20% of patients diagnosed with pancreatic cancer are initially staged as resectable, it is necessary to evaluate new therapeutic approaches. Hence, neoadjuvant (radio)chemotherapy is a聽promising therapeutic option, especially in patients with a聽borderline resectable tumor. The aim of this non-randomized, monocentric, prospective, phase聽II clinical study was to assess the prognostic value of fu...
#1Ulla Klaiber (Heidelberg University)H-Index: 18
#2Eva S. Schnaidt (Heidelberg University)H-Index: 1
Last. Thilo HackertH-Index: 57
view all 11 authors...
: MINI: We analyzed prognostic factors after neoadjuvant therapy and resection in 280 patients with initially unresectable pancreatic cancer-the largest single-center study reported. We found that preoperative CA 19-9 levels, lymph node status, presence of distant metastases, and vascular involvement were all independent overall survival predictors, but not resection margin status. OBJECTIVE: To evaluate the impact of clinical and pathological parameters, including resection margin (R) status, o...
#1Haijie Hu (Sichuan University)H-Index: 4
#2Yayun Zhu (Fudan University)H-Index: 3
Last. Jun Yu (Johns Hopkins University)H-Index: 138
view all 10 authors...
ABSTRACT Backgroud The frequency and significance of the germline variants in DNA damage repair genes still need to be elucidated in patients with sporadic pancreatic ductal adenocarcinoma (PDAC). Our purpose was to determine whether germline variants in DNA damage repair genes were associated with survival of patients with sporadic PDAC. Study Design We retrospectively identified 854 patients with sporadic PDAC with germline DNA sequenced in targeted 22 DNA damage repair genes by next-generatio...
Cited By1
#1Anna Nie脽en (Heidelberg University)H-Index: 3
#2Thilo Hackert (Heidelberg University)H-Index: 57
BACKGROUND The d evelopment of surgical techniques and specialization and specifically complication management in pancreatic surgery have improved surgical outcomes as well as oncological results in pancreatic surgery in recent decades. Historical morbidity and especially mortality rates of up to 80% have decreased to below 5% today. This review summarizes the current state of the art in pancreatic cancer surgery. METHODS The present literature and clinical experience are summarized to give an o...
This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.